Please login to the form below

Not currently logged in

Cidara Therapeutics makes senior appointments

Paul Daruwala and James Balkovec join the biotech

edit-Cidara-Paul-DaruwalaBiotech Cidara Therapeutics has named Paul Daruwala as chief commercial officer and James Balkovec as senior VP of research.

Daruwala (pictured) has over 22 years of experience in the biopharma industry and will lead Cidara's commercial and business development strategies and execution.

He joins from BMS, where he served as VP of the US viral hepatitis franchise, which is responsible for leading the US launch platform in hepatitis C and running the hepatitis B business for Baraclude.

Prior to BMS, Daruwala spent 18 years at Merck in a range of US and global commercial leadership roles in areas including anti-inflammatory products, business development and sales management.

Balkovec has over 28 years of experience in the biopharma industry and has extensive experience within drug discovery. He also joins from Merck, where he has served as senior scientific director and team leader, managing programmes in areas including infectious disease, metabolic syndrome and thrombosis disease.

Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.

Cidara focuses on the discovery, development and commercialisation of novel anti-infectives for the treatment of diseases that are not adequately addresses by current available therapies.

2nd March 2015

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?